Preparation of Liquid Crystalline Molecularly Imprinted Polymer Coated Metal Organic Framework for Capecitabine Delivery
Source abstract
Abstract
Abstract A novel molecularly imprinted polymer (MIP) coated metal organic framework (MOF) containing a liquid crystalline (LC) monomer is successfully synthesized for use in drug delivery systems. In this study, [Cu3(BTC)2(H2O)3] n (HKUST‐1) is chosen as the MOF support owing to its large pore volume, good diffusion, and thermostability. 4‐Methyl phenyl dicyclohexyl ethylene (MPDE) is used as a LC monomer to increase the solvent‐responsive floating of the composite. The preparation conditions of HKUST‐1@LC‐MIP with capecitabine (CAPE) as a template, including the types of functional monomer, the ratio between template and functional monomer, as well as the content of MPDE, are investigated. Characterizations of the HKUST‐1@LC‐MIP are explored using scanning electron microscopy and transmission electron microscope images, Fourier transform infrared spectroscopy, thermal gravimetric analysis, X‐ray diffraction, and nitrogen adsorption. Compared to the HKUST‐1, the HKUST‐1@LC‐MIP shows better stability in aqueous solution. In vitro release studies of CAPE of HKUST‐1@LC‐MIP show zero‐order release of profiles at the loaded concentration of 500 µg mL−1. From in vivo pharmacokinetic studies, the HKUST‐1@LC‐MIP displays higher relative bioavailability. It turns out that the HKUST‐1@LC‐MIP possesses the properties of controlled release and has the potentials for oral administration.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Metal-Organic Frameworks: Synthesis and Applications · Lanthanide and Transition Metal Complexes · Analytical chemistry methods development
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics) School of Pharmacy Tianjin Medical University Tianjin 300070 China
Funding
National Natural Science Foundation of China
References (55)
Show source-provided references
1. 10.1016/j.drudis.2016.10.00110.1016/j.drudis.2016.10.001 ↗
2. 10.1039/C6CS00724D10.1039/C6CS00724D ↗
3. 10.1016/j.chroma.2016.07.01510.1016/j.chroma.2016.07.015 ↗
4. 10.1016/j.bios.2015.12.04010.1016/j.bios.2015.12.040 ↗
5. 10.1039/c3cc48275h10.1039/c3cc48275h ↗
6. 10.1021/acsami.7b1652210.1021/acsami.7b16522 ↗
7. 10.1021/ie101312k10.1021/ie101312k ↗
8. 10.1021/cm400798p10.1021/cm400798p ↗
9. 10.4314/bcse.v31i3.910.4314/bcse.v31i3.9 ↗
10. 10.1021/ar200028a10.1021/ar200028a ↗
11. 10.1002/adfm.20150526010.1002/adfm.201505260 ↗
12. 10.1002/chem.20170190410.1002/chem.201701904 ↗
13. 10.1002/chem.20130014410.1002/chem.201300144 ↗
14. Yan N. L. · Chem. Res. Chin. Univ. · 2012 · 28 · 555
15. 10.1007/s10570-015-0754-410.1007/s10570-015-0754-4 ↗
16. 10.1680/jsuin.15.0001710.1680/jsuin.15.00017 ↗
17. 10.1016/j.inoche.2017.03.02710.1016/j.inoche.2017.03.027 ↗
18. 10.1016/j.synthmet.2017.04.00910.1016/j.synthmet.2017.04.009 ↗
19. 10.1166/jnn.2016.1081110.1166/jnn.2016.10811 ↗
20. 10.1039/c0jm01770a10.1039/c0jm01770a ↗
21. 10.1039/C6CS00061D10.1039/C6CS00061D ↗
22. 10.2174/156720181366616010112023810.2174/1567201813666160101120238 ↗
23. 10.1016/j.talanta.2017.12.00910.1016/j.talanta.2017.12.009 ↗
24. 10.1021/acs.jafc.6b0542910.1021/acs.jafc.6b05429 ↗
25. 10.1016/j.ultsonch.2016.06.03310.1016/j.ultsonch.2016.06.033 ↗
26. 10.1021/ma99059210.1021/ma990592 ↗
27. 10.1007/s00216-015-8510-z10.1007/s00216-015-8510-z ↗
28. 10.1016/j.aca.2006.12.04210.1016/j.aca.2006.12.042 ↗
29. 10.1080/0267829070175156610.1080/02678290701751566 ↗
30. 10.1016/j.chroma.2012.03.04110.1016/j.chroma.2012.03.041 ↗
31. 10.1016/j.chroma.2013.08.02410.1016/j.chroma.2013.08.024 ↗
32. 10.1016/j.ijpharm.2017.09.00810.1016/j.ijpharm.2017.09.008 ↗
33. 10.1016/j.ejpb.2018.02.01210.1016/j.ejpb.2018.02.012 ↗
34. 10.1016/j.eurpolymj.2017.11.02110.1016/j.eurpolymj.2017.11.021 ↗
35. 10.1016/j.ejca.2017.02.02410.1016/j.ejca.2017.02.024 ↗
36. 10.1016/j.clcc.2015.12.00810.1016/j.clcc.2015.12.008 ↗
37. 10.1016/S1470-2045(18)30194-310.1016/S1470-2045(18)30194-3 ↗
38. 10.4251/wjgo.v2.i8.31110.4251/wjgo.v2.i8.311 ↗
39. 10.1038/ncponc124010.1038/ncponc1240 ↗
40. 10.3109/1556952100369958510.3109/15569521003699585 ↗
41. 10.14312/2052-4994.2013-3410.14312/2052-4994.2013-34 ↗
42. 10.1016/j.ejca.2013.03.00410.1016/j.ejca.2013.03.004 ↗
43. 10.2147/PPA.S3675710.2147/PPA.S36757 ↗
44. 10.1039/c0cs00084a10.1039/c0cs00084a ↗
45. 10.1021/ma101013c10.1021/ma101013c ↗
46. 10.1016/j.micromeso.2014.03.00410.1016/j.micromeso.2014.03.004 ↗
47. 10.1126/science.283.5405.114810.1126/science.283.5405.1148 ↗
48. 10.1039/c1cc12935j10.1039/c1cc12935j ↗
49. 10.1351/pac19855704060310.1351/pac198557040603 ↗
50. 10.1021/acsami.6b1107410.1021/acsami.6b11074 ↗
51. 10.1007/s11164-016-2526-710.1007/s11164-016-2526-7 ↗
52. 10.1016/S1387-1811(02)00609-110.1016/S1387-1811(02)00609-1 ↗
53. 10.1021/cm301427w10.1021/cm301427w ↗
54. 10.1016/j.ijpharm.2015.10.03110.1016/j.ijpharm.2015.10.031 ↗
55. 10.1016/S0168-3659(01)00248-610.1016/S0168-3659(01)00248-6 ↗